Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited, founded in 1983 and headquartered in Pune, Maharashtra, operates in the pharmaceuticals industry with a workforce of 10,852 employees and a strong presence in over 70 countries.
Company Overview
Emcure Pharmaceuticals Limited is a prominent player in the pharmaceuticals industry, founded in 1983. The company operates with a workforce of 10,852 employees as of September 30, 2023, and is classified as a very large enterprise with a team size of 7,318. Emcure is headquartered in Pune, Maharashtra, India, and emphasizes its commitment to innovation, encapsulated in its motto 'Success Through Innovation'. The company has established a significant presence in the Indian pharmaceutical market with over 350 brands.
Global Operations
Emcure Pharmaceuticals operates in over 70 countries worldwide, with representative offices in Russia, Myanmar, Vietnam, Ghana, Kazakhstan, and Morocco. The company has subsidiaries in eight countries, including Dubai, Brazil, South Africa, Singapore, Australia, Turkey, Peru, and Nigeria. Additionally, Emcure has established offices in the United States, United Kingdom, and Canada, reflecting its commitment to expanding its global footprint, particularly in European markets.
Products and Therapeutic Areas
Emcure Pharmaceuticals develops and markets a diverse range of pharmaceutical products across several major therapeutic areas. The company focuses on key areas such as gynaecology, cardiology, anti-infectives, vitamins, minerals and nutrients, diabetes, anti-retrovirals, biologics, and mRNA vaccines. Emcure's differentiated product portfolio includes orals, injectables, and biotherapeutics, supported by a vertically integrated supply chain that encompasses production facilities for active pharmaceutical ingredients (APIs), biologics, and formulations.
Research and Development
Emcure Pharmaceuticals maintains a robust research and development framework, employing approximately 500 qualified scientists across five dedicated research facilities. The company focuses on API, formulation, and biotechnology research, which supports its innovative product development. Emcure has launched six biologics in both domestic and international markets, showcasing its commitment to advancing healthcare solutions.
Regulatory Approvals and Sustainability Initiatives
Emcure Pharmaceuticals has received various regulatory approvals for its manufacturing facilities, including certifications from USFDA, UK MHRA, Health Canada, and ANVISA Brazil. The company also emphasizes sustainability through environmental and safety management initiatives, reflecting its commitment to responsible manufacturing practices. Emcure has been recognized for its marketing, manufacturing, and HR practices, including the Silver Impact Award at Pronto Consult Award for Vylda in 2022.